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Mutations in the FMR1 gene have been associated with developmental or neurodegenerative disorders.
The full mutation (>200 CGG repeats) results in Fragile X syndrome, the most common inherited cause of
intellectual disability, while the premutation (55–200 CGG repeats) can lead to a range of problems includ-
ing fragile X-associated tremor/ataxia syndrome (FXTAS). Recently, a new distinctive name was proposed
to recognize the associated disorders commonly found in premutation carriers and extensively reported
in co-morbidities studies: fragile X-associated neuropsychiatric disorders (FXAND). This paper will present
a case report of a female premutation carrier with a complex psychiatric history, chronic pain, and sleep
disturbances consistent with Fragile X-associated neuropsychiatric disorders.
First draft submitted: 3 December 2018; Accepted for publication: 14 March 2019; Published online:
24 May 2019
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Fragile X syndrome is caused by the amplification of CGG repeats in the fragile X mental retardation 1 (FMR1)
gene. Mutations in the FMR1 gene are associated with developmental disorders in children and neurodegenerative
problems in older populations. The full mutation (>200 CGG repeats) in the FMR1 gene results in the fragile
X syndrome (FXS), which is the most common inherited cause of intellectual disability and autism spectrum
disorder. The premutation (55–200 CGG repeats), which is found in approximately 1 in 200 women and 1 in 400
men [1], can also result in problems linked to the elevated levels of the FMR1 mRNA leading to mRNA toxicity
and occasionally mildly deficient FMRP levels [2]. Associated disorders among premutation carriers have been
previously named, including fragile X-associated primary ovarian insufficiency (FXPOI), a condition that occurs
in an estimated 16–20% of carriers and characterized by menopause before 40 years old [3,4], as well as fragile
X-associated tremor/ataxia syndrome (FXTAS), a neurodegenerative condition which is diagnosed in about 16%
of females and 40% of older male premutation carriers [5–7]. However, there have been increasing reports of female
premutation carriers who present with a variety of neurologic, psychiatric, sleep and autoimmune conditions,
which has recently been called fragile X-associated neuropsychiatric disorders (FXAND). This group of conditions,
primarily neuropsychiatric in presentation, affects approximately 50% of carriers [8]. This case report illustrates
many of the conditions associated with FXAND in a woman with the premutation.
Materials & methods
This patient was evaluated as part of the Fragile X Treatment and Research Center located at the University
of California Davis MIND Institute for management of Fragile X disorders. Detailed medical history, physical
and neurological examinations, and genetic testing were done. The neurological examination was carried out by
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a medical doctor and included evaluating cranial nerve function, reflexes, muscle tone, rigidity, sensation, gait,
coordination and the presence of abnormal movements. The patient signed an informed consent form approved
by the Institutional Review Board (IRB) to have her case history published. Here, we describe the patient’s medical
history, neuropsychiatric symptoms, genetic information, and findings on medical and neurological evaluations.
Molecular measures
CGG repeat sizes and activation ratio were determined using PCR amplification and southern blot analysis gene
according to the conditions described in Tassone et al. (2008) and Filipovic-Sadic (2010) [9,10]. FMR1 mRNA
expression levels were determined by quantitative reverse transcription polymerase chain reaction (RT-PCR) as
detailed in Tassone et al. (2000) [2].
Case report
This is the case of a 55-year-old woman, diagnosed as a premutation carrier with two alleles of 29 and 70
CGG repeats, an activation ratio of 0.62 (which expresses the percent of cell carrying the normal allele on
the active X chromosome), and an FMR1 mRNA expression level of 1.9 (0.04)-fold higher compared with
controls. She presented with longstanding problems in anxiety, depression, inattention, chronic pain and opioid
use. Maternal and birth histories were unremarkable while developmental milestones were achieved within normal
limits. Retrospectively, she reported experiencing anxiety and ‘panic attacks’ in early childhood, as far back as 3 years
old, and these persisted into adulthood. She initially performed well in school despite her dislike of reading, but
experienced more problems in attention, organization, and academics in high school. These resulted in poor grades
and increased parent–child conflict although no diagnosis or treatment were given at that time. These events,
alongside living with a high-achieving sibling who was not a premutation carrier, exacerbated her anxiety and
reportedly led to a negative self image.
She drank alcohol as an adolescent to ostensibly ‘self medicate’ her anxiety and stress due to her poor self image
and conflict with parents regarding her academic difficulties. She was eventually diagnosed with depression and
anxiety in her 20s, and prescribed fluoxetine with beneficial effects. Bupropion Hcl was also given for her depression
between 2000 to 2017 but it eventually stopped working at a dose of 300 mg/day. Throughout adulthood, she
continued to take fluoxetine 40 mg/day.
She experimented with street amphetamines to address her symptoms of inattention. It was only recently that
she was diagnosed with attention-deficit/hyperactivity disorder (ADHD) and prescribed Adderall 20 mg/day, a
preparation of mixed amphetamine salts which improves attention.
Opioid abuse has also been an intermittent problem for many years. She was first treated with hydrocodone
after experiencing postoperative pain from a caesarean section delivery, alleviating both her pain and depression.
Hydrocodone use subsequently increased after stressful events successively occurred including the death of her
father, her son’s diagnosis of autism spectrum disorder (ASD), and her premutation carrier diagnosis. She sought
treatment for alcohol and opioid use in an outpatient program with temporary improvements, but later relapsed,
resulting in her admission to an inpatient rehabilitation program. She experienced another relapse after a year
when her mother passed away. Currently, she reportedly limits her alcohol intake to two drinks a day. She still
uses hydrocodone 5 mg three times a day since her depression reportedly becomes so severe when she stops taking
hydrocodone.
She experienced intermittent low back pain for a period of approximately 20 years, which she attributed to
her involvement in gymnastics when she was younger. But in the last 2 years, she has had chronic pain problems
described as constant pain in her neck and shoulders, right arm and trapezius muscles. There is no history of back
surgery and she was never diagnosed with fibromyalgia. A rheumatologist consultation was done several years ago
and a blood test revealed a positive antinuclear antibodies (ANA) titer at 1:360.
She reportedly had ‘tics’ in childhood described as chewing and repetitively tapping on a table. These ’tics’
decreased after puberty but reappeared with her stress about her mother’s passing. Her tics worsened after Adderall
dosage was increased to 30 mg, thus, the dose was kept at 20 mg.
She had one child who was also a premutation carrier (133 CGG repeats). She never had symptoms of premature
ovarian insufficiency and the onset of menopause was at age 52. Movement-related concerns were reported at age
47 characterized by intermittent tremors while manipulating a computer mouse, although tremors have recently
improved in that she does not notice these. There are no reported symptoms of ataxia although she has tripped a
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Table 1. Summary of medical history.
Diagnosis Age of onset Medication/dose per day
FMR1 premutation (70 CGG repeats) N/A
Anxiety Childhood Fluoxetine 40 mg (ongoing)
Social phobia Childhood
Specific phobia (elevators) Childhood
Depression 20 s Fluoxetine 40 mg (ongoing)
Bupropion 300 mg (2010–2017)
Substance abuse 30 s Alcohol 2+ drinks (ongoing)
Hydrocodone 15 mg (ongoing)
Chronic pain 30 s
ADHD 40 s Adderall 20 mg (ongoing)
Sleep disorder 50 s Trazodone 50–75 mg (ongoing)
Memory deficit 50 s
ADHD: Attention-deficit/hyperactivity disorder; N/A: Not applicable.
few times without falling down. She describes numbness in her fingertips but not in her feet. She also experiences
chronic fatigue, which is alleviated by Adderall.
She has had vasovagal episodes during pregnancy and more recently experienced orthostatic hypotension after
standing up quickly from a sitting position.
Cognitive issues were also reported, characterized by memory problems and word retrieval difficulties, which
began originally at age 38 but worsened in her 50s.
She reported experiencing ‘manic behaviors’ in the past, consistent with the criteria for bipolar disorder in partial
remission on the Structured Clinical Interview for the DSM-5 (SCID-5). She had sleep problems due to racing
thoughts although her sleep improved with intake of trazodone 50–75 mg at night. She refused benzodiazepines
for her sleep problems because of her concern that these could be addictive. She also reported frequent snoring but
has not had a polysomnogram to diagnose sleep apnea.
Her current SCID-5 evaluation documents subthreshold depression on fluoxetine, past polydrug abuse, and
fulfills the DSM-5 criteria for social phobia and specific phobia for elevators.
She continues on fluoxetine 40 mg/day, Adderall 20 mg/day, trazodone 75 mg at bedtime and hydrocodone
5 mg three times a day. She has an exercise regimen of at least 4 hours per week and works as a personal trainer,
recognizing the importance of exercise for physical and mental health.
On neurological exam, there were no obvious tremors with finger to nose touching. With positioning, there was
a slight, subclinical tremor in the right hand more than the left. There was no resting tremor. Vibration sense was
normal in all extremities. Primitive reflexes were absent. On tandem gait, she had to leave some space in between
both feet to maintain her balance while executing the motor task. She had an MRI that did not demonstrate any
signs of atrophy or the middle cerebellar peduncle sign, but it showed slight white matter disease in the pons on
the right hemisphere and in the insula. Her corpus callosum was without atrophy but with slight involvement of
the splenium and hyperintensities on T2, representing white matter disease.
She does not meet diagnostic criteria for FXTAS; however, most of her symptoms involve neuropsychiatric
problems, therefore putting her in the FXAND diagnostic category. See Table 1 for a summary of her medical
history.
Discussion
Here, we present a case of an adult female premutation carrier with a lifelong history of anxiety and intermittent
depression consistent with FXAND [8] who does not meet the criteria for FXTAS [11,12]. Her case will add to the
clinical data on FXAND, a recently described fragile X-associated disorder.
FXAND is a proposed umbrella term that represents the neuropsychiatric conditions associated with fragile X
premutation carriers. It is not limited to one entity but includes various neuropsychiatric disorders. It primarily
presents as neuropsychiatric symptoms in premutation carriers who do not have the clinical signs of FXTAS, such
as significant action tremor and/or cerebellar ataxia, in addition to white matter disease on MRI and white matter
hyperintensities in the middle cerebellar peduncles (MCP) [8,11,12]. Neuropsychiatric problems in FXAND emerge
before the neurological problems develop in FXTAS and onset is typically at an earlier age than FXTAS [8].
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Due to the presence of a 70 CGG repeat allele, she was subsequently diagnosed as a premutation carrier. The
relationship between CGG repeats and the prevalence of major depressive disorder is curvilinear. This means that
the middle range of 70–100 repeats confers the greatest risk, while repeats on the lower end and higher end of the
premutation range confer lower risks of psychiatric problems [13].
As a premutation carrier with major depression that meets the DSM-5 criteria, she is labeled as suffering from
FXAND due to the association of her depression with the premutation carrier status. Moreover, she experienced
a constellation of neuropsychiatric problems that is greater in number and severity than the usual patient with
FXAND. The number of neuropsychiatric conditions present in this patient further strengthens the association of
these disorders with the umbrella term FXAND seen in a proportion of premutation carriers.
The neuropathological mechanisms that lead to neuropsychiatric disorders of FXAND are still unclear, although
the mechanisms underlying FXTAS may shed some light into this. Problems associated with the premutation
are related to the RNA toxicity because of elevated FMR1-mRNA. Neurons of premutation carriers are more
vulnerable to environmental toxins [12] and more neuronal death is seen in cell cultures [14]. Ca++ dysregulation
and elevated cytoplasmic Ca++ levels are also present in premutation neurons [15], which may be associated with
the mitochondrial dysfunction that worsens at the onset of FXTAS [16,17]. Chronic DNA damage repair and the
formation of FMRpolyG, a toxic protein [18], are also related to the toxicity of the premutation that leads to the
neurodegenerative process in FXTAS. Similar neuropathological mechanisms may be found in FXAND resulting
in the dysfunction of neural systems responsible for behavior and emotion regulation. A recent paper by Brown
et al. (2019) compared 17 male carriers without FXTAS to 17 age-matched controls (ages 24–70) and found
higher rates of psychopathology in the carriers than controls. In addition, functional magnetic resonance imaging
(fMRI) studies demonstrated remarkably lowered activation patterns to emotional stimuli compared with controls.
These findings did not correlate or change with age. Rather, they appear to represent life span problems of a
neurodevelopmental origin perhaps related to neuronal connectivity deficits in carriers [19].
The patient reported experiencing anxiety from childhood and intermittent depression with multiple psychoso-
cial stressors, consistent with findings about the developmental trajectory and risk factors associated with the
premutation. Higher rates of anxiety disorder are seen among FMR1 premutation carriers compared to the general
population. A lifetime prevalence for anxiety disorder in males with FXTAS is 50% [20], and about 40–47% in
carriers without FXTAS [21]. These anxiety symptoms are typically present in adolescence, and approximately 50%
of female premutation carriers would have met criteria for anxiety disorder before 18 years old [22]. Another study
looking at male and female carriers between 4 and 22 years old estimated that 70% fulfilled the criteria for at least
one type of anxiety disorder in contrast to 9.8% in the general population. Psychosocial stressors heighten the risk
for anxiety, including knowing that one is a carrier [23], or parenting a child with problem behaviors [22]. In premu-
tation carriers with FXTAS, anxiety is associated with progressive decline in cognitive abilities and hippocampal
atrophy, as neurodegenerative processes detrimentally impact on neural systems underpinning executive control
and emotion regulation [20]. Depression is also frequently reported by carriers. The lifetime prevalence of major
depressive disorder is approximately 40% among premutation carriers without FXTAS [22,24] and with FXTAS [20].
Male premutation carriers without FXTAS are more likely to rate themselves higher on depression scales relative to
the normative population [20], with depressive symptoms predicted to worsen over time [25]. Depressive symptoms
are also aggravated by chronic stressors including parenting a child with FXS [22] and comorbid medical conditions
experienced by the carrier.
The patient had ADHD symptoms since childhood, but was not diagnosed nor treated then, so she turned to
street amphetamines to self medicate. ADHD is common in premutation carriers [25] and occurs in over 50% for
those who present clinically. Attention deficits are also more frequently detected in carriers than their noncarrier
sibling – with more males (41%) demonstrating problems compared to females (18.5%) [26]. Hyperactivity may
decline over time although inattentive symptoms may endure [27]. The FMR1mutation is a factor that may increase
the risk for ADHD symptoms so this is included in FXAND [28].
Pain symptoms are often reported by adult premutation carriers. Fibromyalgia can occur in up to 40% of women
with FXTAS [29]. The mechanism through which female premutation carriers develop fibromyalgia is via the
alteration of pain neurotransmission through pain dysregulation, resulting from the damaging effects of increased
rates of transcription of expanded FMR1 mRNA [30]. Both the ADHD and pain symptoms have led to chronic
substance abuse in this history and these problems have been mentioned in the literature regarding co-morbidities
in carriers [31,32]. They have also been included in diagnostic entities covered by FXAND. Additionally, higher
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rates of alcohol abuse have been documented in carriers, placing them at further risk for other neuropsychiatric
co-morbidities [33].
The patient reported reading difficulties due to inattention and experienced academic problems, although she
was never evaluated or given a diagnosis of a learning disorder. While not necessarily psychiatric, her learning
problem was a major stressor during adolescence which could have increased her risk for anxiety and depression.
She also reported cognitive issues as an adult related to memory and word retrieval problems. Cognitive profiles
of premutation carriers are varied, in that some may have normal cognitive functioning while others may present
with a lower verbal intelligence quotient (IQ) scores. Information about learning disorders is minimal although
arithmetic difficulties have been reported in females premutation carriers [34].
Chronic fatigue is common among carriers even before the onset of FXTAS, probably secondary to themitochon-
drial dysfunction [35,36]. Moreover, CNS volumetric changes occur throughout the lifetime in carriers particularly
in the cerebellum and brainstem. Some of the patient’s symptoms such as intermittent tremor are likely related
to the neurological findings on MRI. White matter disease in the CNS can occur even before the symptoms of
FXTAS emerge [11], and this patient demonstrates white matter disease in the insula and in the splenium of the
corpus callosum.
Sleep disturbances in premutation carriers are also frequent. These may be caused by their anxiety and depression,
or these could also be associated with the GABA deficits documented in premutation carriers [37] secondary to a
mild FMRP deficit or to the RNA toxicity. There is also an increased risk of sleep apnea in premutation carriers [38],
which affects restorative sleep. This may play a role in the chronic fatigue they experience and predispose them to
more attention and memory problems.
In regard to the patient’s son, although he does not have the full mutation, he has ASD which is seen in boys
with the premutation [25]. This also comes under the diagnoses included in FXAND [8].
In sum, this is a case of a premutation carrier with complex neuropsychiatric symptoms consistent with FXAND
that missed early detection leading to delayed or inconsistent interventions. Her neuropsychiatric co-morbidities,
together with the challenges of parenting, the impact of her premutation diagnosis, and her experience of losing
her parents, resulted in complex stresses that exacerbated the neurobiological vulnerabilities associated with the
premutation.
Conclusion
This case report provides a clinical example of complex neuropsychiatric symptoms associated with FXAND,
which can be severe, lifelong, and require intensive counseling and pharmacotherapy. Individuals with the FMR1
premutation are at an increased risk for developing anxiety, depression, ADHD, substance abuse, and medical issues
related to pain, chronic fatigue, sleep, and autoimmune problems. However, the association of these psychiatric
problems with the premutation is not always acknowledged, resulting in missed diagnoses or suboptimal treatment.
In this case, the patient consequently experienced longstanding neuropsychiatric issues complicated by substance
abuse. This underscores the need for early identification and intervention for carriers at risk.
The diagnosis of FXAND requires FMR1 DNA testing to identify if one is a premutation carrier (55–200
CGG repeats), and a psychiatric evaluation to determine the presence of a neuropsychiatric disorder. These,
along with genetic counseling, can guide treatment. Timely diagnosis is crucial due to the premutation carrier’s
likelihood of developing the co-morbidities discussed here, as well as having children with an FMR1 mutation and
accompanying neuropsychiatric or neurodevelopmental disorders. Conversely, individuals presenting with mood
or anxiety disorders and a family history of FXS, developmental delay, intellectual disability or autism spectrum
disorder should also be screened [33,39].
Further investigations into the neurobiological and molecular underpinnings of FXAND are necessary to clarify
the mechanisms leading to these neuropsychiatric conditions and to fine tune treatments that alleviate these
symptoms.
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Executive summary
• Fragile X-associated neuropsychiatric disorder (FXAND) is an umbrella term that represents the neuropsychiatric
disorders associated with the FMR1 premutation, which include anxiety, depression, ADHD, obsessive compulsive
disorder, chronic fatigue, insomnia, chronic pain and/or fibromyalgia.
• The neuropathological mechanisms leading to neuropsychiatric disorders of FXAND may be related to
mitochondrial dysfunction secondary to RNA toxicity caused by elevated FMR1-mRNA. These are likely
developmental and not neurodegenerative.
• FXAND can be mild or severe, and lifelong. Problems associated with FXAND usually respond well to counseling
and pharmacotherapy.
• Anxiety, depression, and attention-deficit/hyperactivity disorder (ADHD) are commonly associated with the FMR1
premutation.
• In premutation carriers with fragile-X-associated tremor/ataxia syndrome, anxiety is common and is associated
with an increase in hippocampal atrophy.
• Psychosocial stresses could increase the risk of developing anxiety and depression in premutation carriers.
• ADHD and chronic pain symptoms can potentially lead to chronic substance abuse in premutation carriers.
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